It is imperative to encourage more companies to manufacture minimally invasive devices, point-of-care products, and medical devices to support the NIMP.
The NIMP 2030 promotes integration of value chains for better local production of active pharmaceutical ingredients (API), vaccines, insulin, and medical devices.